Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Safety Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy

NCT00179608 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00179608
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00179608 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Safety Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Completed
Start date
September 1, 2005
Completion date
June 1, 2007
Enrollment
28
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma